Xenon

Xenon Pharmaceuticals Announces Publication of Results from XEN1101 Phase 2b “X-TOLE” Clinical Trial in Peer-Reviewed Journal Article in JAMA Neurology

Retrieved on: 
Monday, October 9, 2023

VANCOUVER, British Columbia, Oct. 09, 2023 (GLOBE NEWSWIRE) -- Xenon Pharmaceuticals Inc. (Nasdaq:XENE), a neurology-focused biopharmaceutical company, today announced the medical journal JAMA Neurology has published peer-reviewed efficacy and safety results from the X-TOLE Phase 2b randomized clinical trial of XEN1101, a novel potassium channel opener, in adults with focal epilepsy.

Key Points: 
  • VANCOUVER, British Columbia, Oct. 09, 2023 (GLOBE NEWSWIRE) -- Xenon Pharmaceuticals Inc. (Nasdaq:XENE), a neurology-focused biopharmaceutical company, today announced the medical journal JAMA Neurology has published peer-reviewed efficacy and safety results from the X-TOLE Phase 2b randomized clinical trial of XEN1101, a novel potassium channel opener, in adults with focal epilepsy.
  • Importantly, the efficacy and safety findings of this clinical trial supported the further clinical development in epilepsy of XEN1101, which is currently being evaluated in Phase 3 clinical trials in patients with focal onset seizures (FOS) and primary generalized tonic-clonic seizures.
  • Mr. Ian Mortimer, Xenon’s President and Chief Executive Officer, stated, “We are pleased to report that the peer-reviewed results from our Phase 2b X-TOLE study of XEN1101 in adults with focal epilepsy have been published in the prestigious JAMA Neurology journal.
  • The article entitled “Efficacy and Safety of XEN1101, a Novel Potassium Channel Opener, in Adults With Focal Epilepsy A Phase 2b Randomized Clinical Trial” was posted today on the JAMA Neurology website .

Xenon Pharmaceuticals to Present at Jefferies Inaugural Biotech CNS/Neuro Summit

Retrieved on: 
Friday, October 6, 2023

A live webcast of the company presentation will be available on the “ Investors ” section of Xenon's website and posted for replay following the event. The above listed dates and times are subject to change.

Key Points: 

A live webcast of the company presentation will be available on the “ Investors ” section of Xenon's website and posted for replay following the event. The above listed dates and times are subject to change.

NASA’s Psyche—Maxar Space’s First Deep Space Spacecraft— Performing Well After Launch

Retrieved on: 
Saturday, October 14, 2023

Maxar Space, provider of comprehensive space solutions and secure, precise, geospatial intelligence, built the unique spacecraft chassis based on the Maxar 1300™ series bus, the world’s most trusted space platform.

Key Points: 
  • Maxar Space, provider of comprehensive space solutions and secure, precise, geospatial intelligence, built the unique spacecraft chassis based on the Maxar 1300™ series bus, the world’s most trusted space platform.
  • The Maxar Space-built Psyche chassis spread its two solar arrays and successfully started maneuvers toward the asteroid belt.
  • (Photo: Maxar Space)
    This Maxar 1300 spacecraft is one of the lightest and smallest ever, showing the versatility of the platform.
  • “Psyche will break records for deep space travel using SEP,” said Chris Johnson, CEO for Maxar Space.

Improving Payment Acceptance Efficiencies Headlines the Agenda at the 2023 nexo standards Annual Conference

Retrieved on: 
Monday, October 9, 2023

As payment acceptance technology and solutions continue to evolve rapidly, identifying and driving system efficiencies is a key priority for the payment community.

Key Points: 
  • As payment acceptance technology and solutions continue to evolve rapidly, identifying and driving system efficiencies is a key priority for the payment community.
  • It is also the focus for the nexo annual conference , which takes place in Dublin on 18 October.
  • A keynote speaker from Mastercard will share real-world efficiencies to reduce costs and future-proof innovations achieved through nexo standards.
  • nexo standards is a community of leading international payment experts spanning Europe, America, Africa and the Middle East working to simplify and enable payment acceptance interoperability by removing decades of fragmentation.

Xenon Pharmaceuticals to Present at TD Cowen’s 3rd Annual Novel Mechanisms in Neuropsychiatry Summit

Retrieved on: 
Thursday, September 14, 2023

VANCOUVER, British Columbia, Sept. 14, 2023 (GLOBE NEWSWIRE) -- Xenon Pharmaceuticals Inc. (Nasdaq:XENE), a neurology-focused biopharmaceutical company, today announced that the company will present at TD Cowen’s 3rd Annual Novel Mechanisms in Neuropsychiatry Summit to be held on September 20, 2023.

Key Points: 
  • VANCOUVER, British Columbia, Sept. 14, 2023 (GLOBE NEWSWIRE) -- Xenon Pharmaceuticals Inc. (Nasdaq:XENE), a neurology-focused biopharmaceutical company, today announced that the company will present at TD Cowen’s 3rd Annual Novel Mechanisms in Neuropsychiatry Summit to be held on September 20, 2023.
  • Company Fireside Chat Presentation Details:

Xenon Pharmaceuticals Announces Upcoming Investor Webinar with Leading Key Opinion Leaders to Discuss XEN1101 and Major Depressive Disorder

Retrieved on: 
Tuesday, September 12, 2023

Participants can register and access the webinar on the Investors section of Xenon’s website.

Key Points: 
  • Participants can register and access the webinar on the Investors section of Xenon’s website.
  • Sanjay J. Mathew, MD, Marjorie Bintliff Johnson and Raleigh White Johnson, Jr. Vice Chair for Research Professor of Psychiatry & Behavioral Sciences Menninger Department of Psychiatry & Behavioral Sciences at Baylor College of Medicine
    James W. Murrough, MD, PhD, Professor of Psychiatry and Neuroscience Director, Depression and Anxiety Center for Discovery and Treatment Icahn School of Medicine at Mount Sinai
    A live webcast of the company presentation will be available on the “ Investors ” section of Xenon's website and posted for replay following the event.
  • The above listed dates and times are subject to change.

Polarean Partners with VIDA to Streamline Adoption of Advanced MRI of the Lungs

Retrieved on: 
Friday, September 8, 2023

The companies are partnering to develop solutions that further enable the Polarean xenon 129 MRI platform to accelerate clinical and research use.

Key Points: 
  • The companies are partnering to develop solutions that further enable the Polarean xenon 129 MRI platform to accelerate clinical and research use.
  • “Furthermore, this partnership perfectly aligns with our objective of extending the reach of XENOVIEW™ MRI, to provide tools to physicians that treat patients suffering from chronic lung disease.”
    “VIDA and Polarean are natural partners.
  • Since the technology is based on MRI, it does not expose patients to any ionizing radiation and its associated risks.
  • The dose of XENOVIEW, created through the Polarean HPX hyperpolarization system, is administered in a single 10-15 second breath-hold MRI procedure.

Christie returns as the Official Digital Projection Partner for the 23rd year

Retrieved on: 
Tuesday, September 12, 2023

TORONTO, Sept. 12, 2023 /PRNewswire-PRWeb/ -- Until September 17, 2023, Christie is illuminating venues, including the Scotiabank Theatre, to help the festival recognize homegrown and international cinema.

Key Points: 
  • Christie® is proud to renew its partnership with the Toronto International Film Festival® (TIFF) for the 23rd consecutive year.
  • TORONTO, Sept. 12, 2023 /PRNewswire-PRWeb/ -- Until September 17, 2023, Christie is illuminating venues, including the Scotiabank Theatre, to help the festival recognize homegrown and international cinema.
  • Returning as its Official Digital Projection Partner, Christie projection solutions are lighting up TIFF venues throughout the city.
  • "As TIFF's Official Projection Partner for the 23rd time, it says a lot about the success of our relationship," says Arlonna Seymour, executive director, Corporate Marketing, Christie.

Have we really found the first samples from beyond the Solar System? The evidence is not convincing

Retrieved on: 
Wednesday, September 6, 2023

He has even hypothesised that the spherules are actually debris from an alien spacecraft.

Key Points: 
  • He has even hypothesised that the spherules are actually debris from an alien spacecraft.
  • I commented at the time that I’d need firm analytical evidence to accept such interpretations.
  • Loeb has now provided a very detailed set of analytical data of 57 spherules in an article submitted to a journal.
  • But it has not yet been subject to the peer review that academics require before they accept research as legitimate.
  • Such particles are referred to as “cosmic spherules” and normally come from asteroids within our Solar System.

Other explanations

    • This is unlikely – iron meteorites from within the Solar System are the most affected by melting and this would explain the results.
    • Other possibilities that Loeb considers are supernovas (infinitely hot exploding stars) and cool, luminous stars (known as “asymptotic giant branch” stars, where cool is still incredibly hot).
    • A supernova results from the catastrophic implosion of a stellar source, producing bursts of neutrons to form new elements.
    • The isotopic composition of those elements has been measured in many grains found in meteorites.
    • But they differ from the spherules described by Loeb because they are very small – only a few microns at most.

Xenon Pharmaceuticals Showcases XEN1101 Epilepsy Program at 35th International Epilepsy Congress

Retrieved on: 
Monday, September 4, 2023

VANCOUVER, British Columbia, Sept. 04, 2023 (GLOBE NEWSWIRE) -- Xenon Pharmaceuticals Inc. (Nasdaq:XENE), a neurology-focused biopharmaceutical company, today announced a summary of its oral and poster presentations at the 35th International Epilepsy Congress (IEC) taking place in Dublin, Ireland from September 2-6, 2023.

Key Points: 
  • Clinically important improvements seen for all patients across important subscales of Seizure Worry, Social Functioning and Medication Effects and for seizure free patients across all QoL subscales
    VANCOUVER, British Columbia, Sept. 04, 2023 (GLOBE NEWSWIRE) -- Xenon Pharmaceuticals Inc. (Nasdaq:XENE), a neurology-focused biopharmaceutical company, today announced a summary of its oral and poster presentations at the 35th International Epilepsy Congress (IEC) taking place in Dublin, Ireland from September 2-6, 2023.
  • Mr. Ian Mortimer, Xenon’s President and Chief Executive Officer, stated, “The IEC meeting in Dublin provides us with another key opportunity to connect with leading epileptologists and showcase our XEN1101 Phase 3 epilepsy program, which includes our ongoing X-TOLE2, X-TOLE3, and X-ACKT clinical trials in focal onset seizures and primary generalized tonic-clonic seizures, respectively.
  • The SFG consisted of 29 patients (approximately 10.5% of those enrolled in the OLE).
  • As a clinician, it is encouraging to see these QoL data, such as the improvements seen across all patients in Medication Effects, as this suggests that patients may benefit from XEN1101, perceiving it to be efficacious and generally well tolerated.